Profile data is unavailable for this security.
About the company
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
- Revenue in USD (TTM)0.00
- Net income in USD-31.42m
- Incorporated2024
- Employees18.00
- LocationTevogen Bio Holdings Inc15 Independence Boulevard, Suite #210WARREN 07059United StatesUSA
- Phone+1 (646) 807-8832
- Fax+1 (302) 655-5049
- Websitehttps://tevogen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plus Therapeutics Inc (USA) | 5.26m | -20.58m | 50.72m | 21.00 | -- | 7.17 | -- | 9.65 | -1.71 | -1.71 | 0.062 | 0.0384 | 0.41 | -- | -- | 250,381.00 | -160.45 | -80.94 | -- | -211.40 | -- | -- | -391.33 | -605.55 | -- | -2.19 | 0.00 | -- | 18.54 | -3.61 | 2.54 | -- | 59.47 | -- |
| Acrivon Therapeutics Inc | 0.00 | -81.75m | 51.43m | 75.00 | -- | 0.3999 | -- | -- | -2.13 | -2.13 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -45.42 | -- | -49.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.40 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -12.36m | 51.82m | 23.00 | -- | -- | -- | -- | -3.03 | -3.03 | 0.00 | -2.94 | 0.00 | -- | -- | 0.00 | -110.62 | -144.86 | -1,640.97 | -870.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 51.98 | -- | -- | -- |
| Tscan Therapeutics Inc | 8.42m | -142.60m | 52.89m | 146.00 | -- | 0.3672 | -- | 6.28 | -1.12 | -1.12 | 0.066 | 2.54 | 0.0276 | -- | -- | 43,417.53 | -46.73 | -38.91 | -51.63 | -43.93 | -- | -- | -1,692.96 | -735.59 | -- | -- | 0.1837 | -- | -86.62 | -- | -42.91 | -- | 25.13 | -- |
| Estrella Immunopharma Inc | 0.00 | -13.50m | 53.17m | -- | -- | -- | -- | -- | -0.3697 | -0.3697 | 0.00 | -0.2605 | 0.00 | -- | -- | -- | -371.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Beyondspring Inc | 0.00 | -7.83m | 53.24m | 40.00 | -- | -- | -- | -- | -0.1942 | -0.0148 | 0.00 | -0.788 | -- | -- | -- | 0.00 | -- | -61.84 | -- | -81.30 | -- | -- | -- | -6,633.90 | -- | -- | -- | -- | -- | -- | 35.26 | -- | 123.69 | -- |
| Kazia Therapeutics Ltd (ADR) | 80.63k | -14.64m | 53.77m | 12.00 | -- | -- | -- | 666.84 | -12.28 | -12.28 | 0.0562 | -3.63 | 0.0083 | -- | 0.0571 | -- | -149.76 | -64.49 | -- | -99.77 | -- | -- | -18,159.65 | -573.31 | -- | -- | -- | -- | -95.09 | 11.58 | 22.69 | -- | -- | -- |
| Instil Bio Inc | 0.00 | -75.08m | 54.19m | 14.00 | -- | 0.45 | -- | -- | -11.39 | -11.39 | 0.00 | 17.76 | 0.00 | -- | -- | 0.00 | -31.00 | -34.59 | -32.06 | -36.59 | -- | -- | -- | -469,515.20 | -- | -19.23 | 0.4127 | -- | -- | -- | 52.50 | -- | 116.55 | -- |
| Metagenomi Therapeutics Inc | 30.91m | -88.74m | 54.80m | 124.00 | -- | 0.3072 | -- | 1.77 | -2.39 | -2.39 | 0.8308 | 4.75 | 0.102 | -- | 39.91 | 153,034.70 | -29.27 | -- | -33.42 | -- | -- | -- | -287.06 | -- | -- | -- | 0.00 | -- | 16.84 | -- | -14.36 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -5.98m | 55.86m | 32.00 | -- | 0.8608 | -- | -- | -0.3607 | -0.3607 | 0.00 | 4.19 | 0.00 | -- | -- | -- | -9.22 | -24.13 | -9.46 | -25.07 | -- | -- | -- | -48,136.22 | -- | -- | 0.00 | -- | -- | -- | 25.56 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -31.42m | 56.40m | 18.00 | -- | -- | -- | -- | -0.2138 | -0.2138 | 0.00 | -0.0396 | 0.00 | -- | -- | 0.00 | -706.86 | -- | -- | -- | -- | -- | -- | -- | -- | -231.10 | -- | -- | -- | -- | 83.01 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -82.71m | 59.06m | 63.00 | -- | 0.4861 | -- | -- | -1.58 | -1.58 | 0.00 | 2.28 | 0.00 | -- | -- | 0.00 | -46.29 | -21.46 | -49.90 | -22.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 14.87 | -- | 43.14 | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.67m | 59.54m | 0.00 | -- | -- | -- | -- | -0.1455 | -0.1455 | 0.00 | -0.1168 | 0.00 | -- | -- | -- | -5,576.42 | -14,417.91 | -- | -- | -- | -- | -- | -- | -- | -684.26 | -- | -- | -- | -- | -106.65 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Tevogen Bio Holdings Inc's reporting currency: US Dollar USD
1.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.07m | 0.54% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 1.06m | 0.53% |
| Geode Capital Management LLCas of 31 Dec 2025 | 553.22k | 0.28% |
| Goldman Sachs Asset Management LPas of 31 Dec 2025 | 220.33k | 0.11% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 189.95k | 0.10% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 174.26k | 0.09% |
| DWS Investments (UK) Ltd.as of 31 Dec 2025 | 173.73k | 0.09% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 132.75k | 0.07% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 106.01k | 0.05% |
| SEI Investments Management Corp.as of 31 Dec 2025 | 90.25k | 0.05% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
